March 17, 2020 / 12:42 AM / 16 days ago

IN BRIEF: Boehringer wins partial reversal on diabetes patents at Fed Circuit

In a partial victory for Boehringer Ingelheim Corp, a federal appeals court on Monday revived a patent on the company’s diabetes drug Tradjenta that had been challenged by generic drugmakers Mylan NV and Aurobindo Pharma Limited.

The U.S. Court of Appeals for the Federal Circuit said a lower court erred in ruling that a Boehringer patent describing a specific diabetes treatment method was a patent-ineligible abstract idea.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below